The seasonal timing of when infants receive the new respiratory syncytial virus (RSV) immunization is crucial for ensuring ...

A single-dose of the respiratory syncytial virus (RSV) vaccine in older adults showed waning efficacy across three seasons of ...

Protection against RSV among infants and birthing parents differed by race and ethnicity, indicating the need to ensure equitable access to RSV products.

Pfizer's Abrysvo and GSK's Arexvy both received FDA-approval b in 2024 to include immunization of adults aged 50 to 59 years at increased risk for RSV disease.

A phase 3 trial involving nearly 25,000 older adults across 17 countries found that a single dose of the RSVPreF3 OA vaccine ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Under direction of Health Secretary Robert F. Kennedy Jr., the CDC is considering changes to its recommendations on vaccines ...

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices ...

Pfizer Inc. announced today that the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) voted to expand its recommendation for the use of ...

The CDC's Advisory Committee on Immunization Practices (ACIP) voted 14-0, with one abstention, on Wednesday to recommend that ...

Adults with respiratory syncytial virus-associated acute respiratory infection (RSV-ARI) are likely to be at a 2.7-fold higher risk of death within one year, warned a study. RSV-ARI refers to a ...

Adults with respiratory syncytial virus-associated acute respiratory infection (RSV-ARI) are likely to be at a 2.7-fold higher risk of death within one year. – IANS New Delhi, April 12 (IANS) Adults ...